中药概念持续拉升，万邦德涨停，康芝药业、天目药业、珍宝岛、吉林敖东等跟涨。 ...

10月10日，康芝药业涨5.24%，截至发稿，报7.23元/股，成交4301.86万元，换手率1.38%，总市值32.91 亿元。 资料显示，康芝药业股份有限公司位于海南省海口国家高新技术产业开发区药谷工业园药谷三路6号及 广州东山广场26楼，成立日期1994年1月20日，上市日期2010年5月26日，公司主营业务涉及以儿童药、 母婴健康用品的研发生产与销售、医疗防护用品等医疗器械为主营业务的国内领先儿童大健康企业。主 营业务收入构成为：儿童药76.16%，成人药20.89%，其他(补充)2.94%。 从康芝药业十大流通股东角度 数据显示，诺安基金旗下1只基金位居康芝药业十大流通股东。诺安多策略混合A（320016）二季度新 进十大流通股东，持有股数190.87万股，占流通股的比例为0.43%。根据测算，今日浮盈赚取约68.71万 元。 诺安多策略混合A（320016）成立日期2011年8月9日，最新规模13.99亿。今年以来收益60.31%，同类 排名752/8166；近一年收益89%，同类排名163/8014；成立以来收益209.4%。 诺安多策略混合A（320016）基金经理为孔宪政、王海畅。 截至发稿 ...

Group 1 - Sichuan Road and Bridge's controlling shareholder plans to reduce its stake by up to 2% of the company's total shares, amounting to approximately 174 million shares [1] - Jinlongyu's shareholder terminates the share transfer agreement, halting the planned transfer of 5.32% of the company's shares [1] - Doli Technology's subsidiary plans to establish a joint venture in Spain with an investment of approximately 505 million yuan, with a 70% stake held by Doli Technology [1][2] Group 2 - Chongqing Pharmaceutical, a subsidiary of Zhongyao Holdings, has received approval for clinical trials of its drug, Clopidogrel Hydrochloride Tablets [3][4] - Dongyangguang plans to jointly increase capital in a subsidiary to acquire 100% of Qinhuai Data China for 28 billion yuan [5] - Kangzhi Pharmaceutical's controlling shareholder intends to transfer 5.0004% of the company's shares at a price of 5.34 yuan per share, totaling approximately 122 million yuan [6] Group 3 - Huali Co., Ltd. announces two shareholders plan to reduce their stakes by a combined total of up to 3.96% of the company's shares [7] - Fangbang Co., Ltd.'s director plans to reduce his stake by up to 15,000 shares, representing 0.1844% of the total shares [8] - China Pacific Insurance suggests issuing HKD-denominated convertible bonds, with proceeds aimed at supporting its main insurance business and strategic initiatives [9] Group 4 - Microchip Biotech's shareholder plans to reduce its stake by up to 3% of the company's total shares [10] - Hongbai New Materials' controlling shareholder intends to reduce its stake by up to 3% due to funding needs [11] - Zhejiang Rongtai clarifies that its sales in the robotics components sector are minimal and will not significantly impact annual net profit [12] Group 5 - ST Tianmao voluntarily withdraws its application for A-share listing, which has been accepted by the Shenzhen Stock Exchange [13] - Qingxin Environment's shareholder plans to reduce its stake by up to 1% of the company's total shares [14] - Lanjik Technology's two shareholders plan to reduce their stakes by a combined total of up to 2% of the company's shares [15] Group 6 - BYD's executives and core personnel collectively increased their holdings in the company by approximately 52.33 million yuan [16] - Trina Solar's subsidiary signs contracts for the sale of 2.48 GWh of energy storage products, marking a significant overseas order [17] - Chutianlong's shareholder plans to reduce its stake by up to 3% of the company's total shares [18] Group 7 - Zhongjuxin's shareholder plans to reduce its stake by up to 2.5% of the company's total shares due to funding needs [19] - ST Hezhong's controlling shareholder is under bail pending trial, but company operations remain unaffected [20] - Shoukai Co., Ltd. reports a signed contract amount of 973 million yuan for August, with cumulative contracts of 13.15 billion yuan for the year [21] Group 8 - Jucheng Co., Ltd.'s shareholder plans to reduce its stake by up to 2.61% of the company's total shares due to personal funding needs [22]

中国经济网北京9月11日讯康芝药业（300086）(300086.SZ)昨日晚间发布公告称，公司于2025年9月9日 接到控股股东海南宏氏投资有限公司(以下简称"宏氏投资")通知，获悉宏氏投资与北京晨乐资产管理有 限公司(代表"晨乐佳享4号私募证券投资基金，基金编号：SGP496")(以下简称"晨乐佳享4号")于2025年9 月9日签订了《海南宏氏投资有限公司与北京晨乐资产管理有限公司(代表"晨乐佳享4号私募证券投资基 金")关于康芝药业股份有限公司之5.0004%股份转让协议》，宏氏投资拟通过协议转让的方式合计将持 有公司的22,758,000股无限售流通股(占公司股份总数的5.0004%)转让给晨乐佳享4号。本次股份协议转 让价格为5.34元/股，股份转让总价款为人民币12,152.772万元。 本次转让前晨乐佳享4号未持有康芝药业股份，本次转让后，晨乐佳享4号将持有康芝药业股份 22,758,000股，占总股本比例5.0004%。 本次协议转让股份未触及要约收购。本次股份协议转让，仅涉及宏氏投资与晨乐佳享4号之间的转让。 本次股权转让不涉及康芝药业控制权变更，本次权益变动不会导致上市公司控股股东、实际控 ...

Group 1 - Dongyangguang plans to jointly increase capital in a subsidiary for the acquisition of 100% equity in Qinhuai Data China, with a total investment of 75 billion yuan [2] - Baiyin Nonferrous Metals is under investigation by the China Securities Regulatory Commission for suspected information disclosure violations [3] - Beida Pharmaceutical intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange [5] Group 2 - ST Tianmao plans to withdraw its A-share listing and transfer to the National SME Share Transfer System after delisting [5] - Goldwind Technology has approved an investment agreement for a 3GW wind-hydrogen-ammonia integration project in Inner Mongolia, with a total investment of approximately 189.2 billion yuan [6] - Langzi Co. has signed an agreement to acquire 67.5% of Chongqing Milan Baiyu Shiguang Medical Beauty Hospital for 92.475 million yuan [7] Group 3 - Dongfang Guoxin is establishing a joint venture with Beijing Shunyi Financial Holdings to focus on computing power infrastructure and services, with a registered capital of 300 million yuan [8] - ST Hezhong's chairman is under bail pending trial, but the company's operations remain unaffected [9] - Kangzhi Pharmaceutical's major shareholder is transferring 22.758 million shares at a price of 5.34 yuan per share, totaling 122 million yuan [9] Group 4 - Shenzhen Airport reported a passenger throughput of 5.807 million in August, a year-on-year increase of 4.07% [10] - Lin Yang Energy won a bid for a project with a total amount of approximately 244.08 million yuan [11] - Fullpower New Materials received a government subsidy of 20 million yuan, which is expected to positively impact its 2025 profits [14] Group 5 - BYD executives and core personnel collectively increased their holdings by 48.82 million shares, totaling 52.3278 million yuan [16] - Hualing Steel's major shareholder increased its stake by 6.90862 million shares, representing a 1% increase in ownership [16]

Core Viewpoint - Kangzhi Pharmaceutical announced a share transfer agreement where its controlling shareholder, Hongshi Investment, will transfer 22,758,000 shares (5.0004% of total shares) to Chenle Jixiang No. 4 at a price of 5.34 RMB per share, totaling approximately 121.53 million RMB [2] Summary by Relevant Sections - **Share Transfer Details** - Hongshi Investment will transfer 22,758,000 unrestricted circulating shares to Chenle Jixiang No. 4 [2] - The transfer price is set at 5.34 RMB per share, amounting to a total of 121.53 million RMB [2] - **Impact on Shareholding Structure** - Post-transfer, Hongshi Investment's shareholding will decrease from 27.2538% to 22.2534% [2] - Chenle Jixiang No. 4 will become a shareholder with over 5% ownership [2]

Core Viewpoint - Kangzhi Pharmaceutical (300086.SZ) announced a share transfer agreement involving 5.0004% of its total shares, indicating a strategic move by its controlling shareholder, Hongshi Investment [1] Group 1: Share Transfer Details - Hongshi Investment notified the company on September 9, 2025, about the signing of a share transfer agreement with Chenle Jiaxiang No. 4 [1] - The agreement involves the transfer of 22,758,000 unrestricted circulating shares, representing 5.0004% of the company's total shares [1] - The transfer price is set at 5.34 RMB per share, totaling approximately 121.52772 million RMB for the entire transaction [1]

Group 1 - The controlling shareholder, Hongshi Investment, plans to transfer 5.0004% of its shares in Kangzhi Pharmaceutical to Beijing Chenle Asset Management Co., Ltd. [1] - The share transfer will be executed through a private agreement, with a price of 5.34 yuan per share [1] - The total transaction amount for the share transfer is 122 million yuan [1]

Group 1 - The controlling shareholder, Hongshi Investment, is transferring 5.0004% of the company's shares at a price of 5.34 CNY per share, totaling 122 million CNY [1] - After the transfer, Hongshi Investment will hold 101 million shares, representing 22.2534% of the company's total share capital [1] - Beijing Chenle Asset Management Co., Ltd. - Chenle Jixiang No. 4 Private Securities Investment Fund will hold 22.758 million shares, accounting for 5.0004% of the company's total share capital [1]

证券代码：300086 证券简称：康芝药业 公告编号：2025-039 康芝药业股份有限公司 关于控股股东协议转让公司部分股权 暨权益变动的提示性公告 本次协议转让各方保证向本公司提供信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露内容与信息披露义务人提供的 信息一致。 特别提示： 1.持有康芝药业股份有限公司(以下简称"康芝药业"、"公司"或"本公司") 股份 124,038,747 股，占总股本比例 27.25%的公司控股股东海南宏氏投资有限公 司（以下简称"宏氏投资"、"转让方"或"甲方"）拟通过协议转让方式将其 持有公司 22,758,000 股无限售流通股（占总股本比例 5.0004%）转让给北京 晨乐资产管理有限公司（代表"晨乐佳享 4 号私募证券投资基金,基金编号： SGP496"）(以下简称"晨乐佳享 4 号"、"受让方"或"乙方"）。本次转让前晨 乐佳享4 号未持有公司股份，本次转让后，晨乐佳享4 号将持有公司股份 22,758,000 股，占总股本比例 5.0004%。 2.本次协议转让股份未触及要约收购。 3.本次股份协议转让，仅 ...